Febuxostat

Febuxostat

• CAS Number: 144060-53-7
• UNSPSC Description: Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout[1][2][3].
• Target Antigen: Xanthine Oxidase
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Metabolic Disease; Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Febuxostat.html
• Solubility: DMSO : 50 mg/mL (ultrasonic)
• Smiles: CC(COC1=CC=C(C=C1C#N)C2=NC(C)=C(S2)C(O)=O)C
• Molecular Weight: 316.37
• References & Citations: [1]Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835-1847.|[2]Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710-F718.|[3]Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69-p78.|[4]Nomura J, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014 Apr 1;4:4554.|[5]Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7.|[6]Khames A, et al. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Eur J Pharmacol. 2017 Jun 15;805:118-124.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched